Gestational methylazoxymethanol acetate administration: A developmental disruption model of schizophrenia
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Animal models are critical for the study of psychiatric disorders since they allow the use of invasive methods that cannot be used for ethical reasons in humans. Currently there are three general models of schizophrenia; (i) those produced with acute pharmacological intervention (i.e. MK-801, ketamine, PCP and amphetamine), (ii) genetic models (i.e. mutant DISC-1, D2-R over expression) and (iii) developmental disruption models (i.e. MAM, neonatal ventral hippocampal lesion, isolation rearing, maternal infection). Here we review evidence for the validity of gestational (day 17) MAM administration as a developmental disruption rodent model of schizophrenia. Offspring from MAM-treated dams are reported to display deficits consistent with those observed in schizophrenia patients, including anatomical changes, behavioral deficits and altered neuronal information processing. Thus gestational MAM administration has been demonstrated to induce a pathodevelopmental process leading to neuroanatomical and behavioral phenotypes consistent with that observed in schizophrenia in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Cellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663
A review of MRI findings in schizophrenia
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00163-3 · Cited by 2,346 · cited 3×
“More specifically, a postmortem reduction in hippocampal volume is one of the more consistent structural abnormalities observed in schizophrenia patients [34,76-79].”
BackgroundCortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Grace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
Self-citationMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
The neuropathology of schizophrenia
Harrison, P. J. (1999) · Brain · doi:10.1093/brain/122.4.593 · Cited by 1,677
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Cited by
Abnormal neural oscillations and synchrony in schizophrenia
Uhlhaas, P. J., & Singer, W. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2774 · Cited by 2,120
Hippocampal sharp wave-ripple: A cognitive biomarker for episodic memory and planning
Buzsáki, G. (2015) · Hippocampus · doi:10.1002/hipo.22488 · Cited by 1,759
Animal models of schizophrenia
Jones, C., Watson, D., & Fone, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01386.x · Cited by 771
Epidemiology-driven neurodevelopmental animal models of schizophrenia
Meyer, U., & Feldon, J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.10.018 · Cited by 372
Schizophrenia: a tale of two critical periods for prefrontal cortical development
Selemon, L. D., & Zecevic, N. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.115 · Cited by 336
Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
Lodge, D. J., & Grace, A. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.001 · Cited by 349
“This model involves the administration of a mitotoxin methylazoxymethanol acetate (MAM) to pregnant female rats, specifically on gestational day 17, which results in a range of anatomical, behavioral and neurochemical deficits that are consistent with those observed in schizophrenia patients (for review see [35]).”
ResultSelf-citationBarch, D. M., Treadway, M. T., & Schoen, N. (2014) · Journal of Abnormal Psychology · doi:10.1037/a0036299 · Cited by 323
Hippocampal-Prefrontal Interactions in Cognition, Behavior and Psychiatric Disease
Sigurdsson, T., & Duvarci, S. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2015.00190 · Cited by 309
GABAergic mechanisms of hippocampal hyperactivity in schizophrenia
Heckers, S., & Konradi, C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.09.041 · Cited by 277
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models
Malone, D. T., Hill, M. N., & Rubino, T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00721.x · Cited by 237
Translating the MAM model of psychosis to humans
Modinos, G., Allen, P., Grace, A. A., & McGuire, P. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.12.005 · Cited by 165
“MAM administration to pregnant rats to disrupt embryonic brain development [8, 9, 12, 23].”
BackgroundSelf-citationPowell, S. B., Sejnowski, T. J., & Behrens, M. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.049 · Cited by 164
“to enduring loss of parvalbumin expression in PVD interneurons”
BackgroundInfluentialDevelopmental pathology, dopamine, stress and schizophrenia
Lodge, D. J., & Grace, A. A. (2011) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2010.08.002 · Cited by 109
Self-citationTracing the development of psychosis and its prevention: what can be learned from animal models
Piontkewitz, Y., Arad, M., & Weiner, I. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.019 · Cited by 108
Du, Y., & Grace, A. A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.101 · Cited by 105
Self-citationPhillips, K. G., Cotel, M. C., McCarthy, A. P., Edgar, D. M., Tricklebank, M., O’Neill, M. J., Jones, M. W., & Wafford, K. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.006 · Cited by 100
Prenatal Expression Patterns of Genes Associated With Neuropsychiatric Disorders
Birnbaum, R., Jaffe, A. E., Hyde, T. M., Kleinman, J. E., & Weinberger, D. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13111452 · Cited by 97
Shah, A., & Lodge, D. J. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.145 · Cited by 87
Self-citationGomes, F. V., Guimarães, F. S., & Grace, A. A. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu018 · Cited by 68
Self-citationPerez, S. M., Carreno, F. R., Frazer, A., & Lodge, D. J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0588-14.2014 · Cited by 65
Self-citationGulchina, Y., Xu, S., Snyder, M. A., Elefant, F., & Gao, W. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14101 · Cited by 56
Schwarz, K., Moessnang, C., Schweiger, J. I., Harneit, A., Schneider, M., Chen, J., Cao, H., Schwarz, E., Witt, S. H., Rietschel, M., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.07.016 · Cited by 18
Metadata
- Authors
- Lodge, D. J., & Grace, A. A.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2009-12-07
- Volume
- 204
- Issue
- 2
- Pages
- 306-312
- ISSN
- 0166-4328 (ISSN-L)
- OpenAlex
- W1964043050
- Cited by
- 215
- References
- 35
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.